Mealey's Emerging Drugs & Devices Bulletin: Glaxo to Pay $3 Billion Stemming from Drug Marketing

Mealey's Emerging Drugs & Devices Bulletin: Glaxo to Pay $3 Billion Stemming from Drug Marketing

BOSTON -GlaxoSmithKline LLC (GSK) agreed today to plead guilty and to pay $3 billion to resolve broad-ranging criminal and civil allegations in Massachusetts federal court regarding the promotion of several prescription drugs, failure to report safety ...read more